Evidence map›Paper›PMID 20923692›Full record

ArticlePeptides2011

The absence of VPAC2 leads to aberrant antibody production in Aspergillus fumigatus sensitized and challenged mice.

Amali E Samarasinghe, Scott A Hoselton, Jane M Schuh

Open access · greenAbstract read
In one paragraph

Article in Peptides, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Amali E SamarasingheNorth Dakota State University, Department of Veterinary and Microbiological Sciences, PO Box 6050-Dept 7690, Fargo, ND 58108-6050, United States. a.samarasinghe@ndsu.edu
Scott A Hoselton
Jane M Schuh
North Dakota State University · US

Funding

TARGETING AND DELIVERYP20RR015566 · NCRR · NORTH DAKOTA STATE UNIVERSITY · PI SIBI, MUKUND P. · 2001 to 2011
$19.0M
Pilot Projects: Core DP30GM103332 · NIGMS · NORTH DAKOTA STATE UNIVERSITY · PI SIBI, MUKUND P. · 2012 to 2016
$4.9M
A novel model of fungal asthma using aeroallergen sensitization and challengeR15AI069061 · NIAID · NORTH DAKOTA STATE UNIVERSITY · PI SCHUH, JANE M. · 2006 to 2006
$214k
NCRR NIH HHS P20 RR015566NIAID NIH HHS 1R15AI69061NIAID NIH HHS R15 AI069061NIGMS NIH HHS P30 GM103332PHS HHS NCRR2P20 RR015566
6 · The paper itself

Abstract

Vasoactive intestinal peptide (VIP) facilitates a "pro-allergy" phenotype when signaling through its G protein-coupled receptor, VPAC(2). We have shown that VPAC(2) knock-out (KO) mice developed an allergic phenotype marked by eosinophilia and elevated serum IgE. Therefore, we hypothesized that the humoral response to allergen challenge in these mice was T(H)2 dominant similar to wild-type (WT) C57BL/6 mice. Antibody responses in WT and KO mice were measured after Aspergillus fumigatus conidia inhalation. In contrast to previous reports, basal levels of serum IgG(2a) and IgA were significantly higher in naïve VPAC(2) KO animals. Antibody availability in the serum as well as the bronchoalveolar lavage fluid after fungal challenge was dominated by the pro-inflammatory isotype IgG(2a) and the mucosal isotype, IgA. IgA localizing cells dominated in the peribronchovascular areas of allergic KO mice while IgE immune complexes were found in WT allergic lungs. This research shows for the first time that VPAC(2) has a significant effect on antibody regulation, in the context of allergy.

Indexed as

Antibody FormationAnimalsAspergillus fumigatusHypersensitivity, ImmediateImmunoglobulin AImmunoglobulin GMiceMice, Inbred C57BLMice, KnockoutReceptors, Vasoactive Intestinal Peptide, Type IIVasoactive Intestinal PeptideImmunoglobulin AImmunoglobulin GReceptors, Vasoactive Intestinal Peptide, Type IIVasoactive Intestinal Peptide

Identifiers

PMID20923692
PMCPMC3299058
OpenAlexW2150375105

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.